From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Regimen
No. of patients
%
Taxane/Cisplatin
191
47.5
Taxane/Cisplatin/5-FU
94
23.4
Irinotecan/5-FU
9
2.2
Oxaliplatin/5-FU
52
12.9
5-FU (oral or infusional fluoropyrimidines)/Cisplatin
21
5.2
Oral fluoropyrimidine
35
8.7
Total
402
100.0